Helix BioPharma Corp. has decided not to proceed with a previously announced equity draw-down subscription facility with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited. The company entered into a non-binding term sheet with GEM on October 15, 2024, and had received shareholder approval for the financing arrangement at its annual general and special meeting on March 26, 2025.
Following a comprehensive evaluation of current market conditions and long-term corporate objectives, Helix determined that the GEM facility no longer aligns with its capital strategy or commitment to maximizing long-term shareholder value. The letter of intent has expired according to its terms, and the company has chosen not to execute binding agreements or pursue the financing with GEM.
This decision is significant because it represents a strategic shift in how the clinical-stage oncology company plans to fund its research and development programs. The terminated facility would have provided Helix with access to up to $50 million in capital through equity issuances over a 36-month period, as detailed in the company's Management Information Circular dated January 31, 2025.
Despite this development, Helix continues to engage in discussions with financial partners to explore alternative financing structures that better align with the company's needs and strategic direction. The company remains committed to securing necessary capital to advance its clinical programs, including Tumor Defense Breaker™ L-DOS47, which has completed Phase Ib studies in non-small cell lung cancer.
The implications of this decision extend beyond Helix's immediate financing needs. For investors and the broader biopharmaceutical industry, it highlights the challenges oncology companies face in securing appropriate funding during volatile market conditions. The company's ability to maintain its clinical development timeline for promising cancer treatments, including its next-generation bi-specific antibody-drug conjugates and pre-IND candidates LEUMUNA™ and GEMCEDA™, may be affected by this financing setback.
As reported in the company's March 26, 2025 news release regarding voting results from its special meeting, shareholders had previously supported the proposed financing arrangement. The reversal of this decision underscores the dynamic nature of capital markets and the need for biopharmaceutical companies to maintain flexibility in their financing strategies while pursuing treatments for hard-to-treat cancers.
